List view / Grid view

Bryan Oronsky

 

article

A “hot” issue: TGF -β and checkpoint inhibitor resistance

In this article, Bryan Oronsky, Chief Development Officer, and Tony…

8 December 2022 | By ,

In this article, Bryan Oronsky, Chief Development Officer, and Tony Reid, Chief Executive Officer of EpicentRx, explain how AdAPT-001 uses tumour cells as a factory to make the TGF-beta trap that it carries. This trap neutralises the immunosuppressive protein, transforming growth factor–β to ‘heat up’ tumours and sensitise them to…